A 2023 SCS study detected overexpression of GAS2L1 and EPCAM in circulating tumor cells and highlighted the potential of GAS2L1 as a novel biomarker for the diagnosis of pancreatic cancer (Zhang et al., 2023). Here, GAS2L1 is linked to familial pancreatic carcinoma.